WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 555952
CAS#: 680611-86-3
Description: SGA360 is a selective AHR modulator, which is a ligand-dependent transcription factor that mediates the toxicity of certain xenobiotics and polyaromatic hydrocarbons.
MedKoo Cat#: 555952
Name: SGA360
CAS#: 680611-86-3
Chemical Formula: C19H17F3N2O2
Exact Mass: 362.1242
Molecular Weight: 362.3522
Elemental Analysis: C, 62.98; H, 4.73; F, 15.73; N, 7.73; O, 8.83
Synonym: SGA360; SGA-360; SGA 360;
IUPAC/Chemical Name: 3-(2,4-dimethoxyphenyl)-1-(2-propen-1-yl)-7-(trifluoromethyl)-1H-indazole
InChi Key: BMIOASGFHBRKJL-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H17F3N2O2/c1-4-10-24-18-14(6-5-7-15(18)19(20,21)22)17(23-24)13-9-8-12(25-2)11-16(13)26-3/h4-9,11H,1,10H2,2-3H3
SMILES Code: FC(C1=CC=CC2=C1N(CC=C)N=C2C3=CC=C(OC)C=C3OC)(F)F
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 10.0 | 27.6 | |
| DMF | 20.0 | 55.2 | |
| Ethanol | 2.0 | 5.52 |
The following data is based on the product molecular weight 362.3522 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Muku GE, Blazanin N, Dong F, Smith PB, Thiboutot D, Gowda K, Amin S, Murray IA, Perdew GH. Selective Ah receptor ligands mediate enhanced SREBP1 proteolysis to restrict lipogenesis in sebocytes. Toxicol Sci. 2019 Jun 21;171(1):146–58. doi: 10.1093/toxsci/kfz140. Epub ahead of print. PMID: 31225620; PMCID: PMC6736396.
2: Muku GE, Lahoti TS, Murray IA, Podolsky MA, Smith KJ, Hubbard TD, Kuzu G, Gowda K, Amin SG, Perdew GH. Ligand-mediated cytoplasmic retention of the Ah receptor inhibits macrophage-mediated acute inflammatory responses. Lab Invest. 2017 Dec;97(12):1471-1487. doi: 10.1038/labinvest.2017.92. Epub 2017 Sep 11. PMID: 28892097; PMCID: PMC5711556.
3: van den Bogaard EH, Podolsky MA, Smits JP, Cui X, John C, Gowda K, Desai D, Amin SG, Schalkwijk J, Perdew GH, Glick AB. Genetic and pharmacological analysis identifies a physiological role for the AHR in epidermal differentiation. J Invest Dermatol. 2015 May;135(5):1320-1328. doi: 10.1038/jid.2015.6. Epub 2015 Jan 20. PMID: 25602157; PMCID: PMC4402116.
4: Smith KJ, Murray IA, Tanos R, Tellew J, Boitano AE, Bisson WH, Kolluri SK, Cooke MP, Perdew GH. Identification of a high-affinity ligand that exhibits complete aryl hydrocarbon receptor antagonism. J Pharmacol Exp Ther. 2011 Jul;338(1):318-27. doi: 10.1124/jpet.110.178392. Epub 2011 Apr 14. PMID: 21493753; PMCID: PMC3126639.
5: Murray IA, Krishnegowda G, DiNatale BC, Flaveny C, Chiaro C, Lin JM, Sharma AK, Amin S, Perdew GH. Development of a selective modulator of aryl hydrocarbon (Ah) receptor activity that exhibits anti-inflammatory properties. Chem Res Toxicol. 2010 May 17;23(5):955-66. doi: 10.1021/tx100045h. PMID: 20423157; PMCID: PMC2871980.
